KR20240011429A - Oral care toothpaste composition containing herbal extract - Google Patents
Oral care toothpaste composition containing herbal extract Download PDFInfo
- Publication number
- KR20240011429A KR20240011429A KR1020220088861A KR20220088861A KR20240011429A KR 20240011429 A KR20240011429 A KR 20240011429A KR 1020220088861 A KR1020220088861 A KR 1020220088861A KR 20220088861 A KR20220088861 A KR 20220088861A KR 20240011429 A KR20240011429 A KR 20240011429A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- toothpaste composition
- weight
- toothpaste
- bacteria
- Prior art date
Links
- 239000000606 toothpaste Substances 0.000 title claims abstract description 50
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000012676 herbal extract Substances 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 39
- 206010006326 Breath odour Diseases 0.000 claims abstract description 27
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 229940007062 eucalyptus extract Drugs 0.000 claims abstract description 14
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims abstract description 10
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 10
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 9
- 201000001245 periodontitis Diseases 0.000 claims abstract description 8
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 7
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 22
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- 229960002684 aminocaproic acid Drugs 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 102000010445 Lactoferrin Human genes 0.000 claims description 7
- 108010063045 Lactoferrin Proteins 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- -1 chlorohydroxyaluminum Chemical compound 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 7
- 229940078795 lactoferrin Drugs 0.000 claims description 7
- 235000021242 lactoferrin Nutrition 0.000 claims description 7
- 239000013521 mastic Substances 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 229940079781 sodium cocoyl glutamate Drugs 0.000 claims description 7
- 229960002920 sorbitol Drugs 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 241000194019 Streptococcus mutans Species 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 5
- 241001135221 Prevotella intermedia Species 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 4
- 241000589886 Treponema Species 0.000 claims description 4
- 230000000052 comparative effect Effects 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 210000000214 mouth Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 7
- 208000002925 dental caries Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 5
- 241000219927 Eucalyptus Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 150000003464 sulfur compounds Chemical class 0.000 description 5
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 244000197975 Solidago virgaurea Species 0.000 description 4
- 235000000914 Solidago virgaurea Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- 244000167222 Acanthopanax sessiliflorus Species 0.000 description 2
- 235000017615 Acanthopanax sessiliflorus Nutrition 0.000 description 2
- 241000269837 Artemisia dubia Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002222 fluorine compounds Chemical class 0.000 description 2
- 208000024693 gingival disease Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 235000012711 vitamin K3 Nutrition 0.000 description 2
- 239000011652 vitamin K3 Substances 0.000 description 2
- 229940041603 vitamin k 3 Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000004210 tooth component Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 유칼립투스 추출물, 쑥 추출물, 황금 추출물, 인삼 추출물, 병풀 추출물 및 티트리 추출물이 혼합된 생약 추출물을 함유하는 구강케어 치약 조성물에 관한 것으로서, 상기 조성물은 충치, 치주염 또는 구취의 원인균에 대한 항균효과가 우수하여 치약 조성물로 용이하게 이용가능하다.The present invention relates to an oral care toothpaste composition containing a herbal extract mixed with eucalyptus extract, mugwort extract, golden extract, ginseng extract, centella asiatica extract, and tea tree extract, wherein the composition has antibacterial properties against bacteria that cause cavities, periodontitis, or bad breath. It is highly effective and can be easily used as a toothpaste composition.
Description
본 발명은 생약 추출물을 함유하는 구강케어 치약 조성물에 관한 것으로서, 보다 자세하게는 유칼립투스 추출물, 쑥 추출물, 황금 추출물, 인삼 추출물, 병풀 추출물 및 티트리 추출물이 혼합된 생약 추출물을 함유하는 구강케어 치약 조성물에 관한 것이다. The present invention relates to an oral care toothpaste composition containing a herbal extract, and more specifically, to an oral care toothpaste composition containing a herbal extract mixed with eucalyptus extract, mugwort extract, goldenrod extract, ginseng extract, centella asiatica extract, and tea tree extract. It's about.
사람의 구강 안에는 400종류 이상의 세균이 번식하고 있으며, 그 균수는 100억개에 달하고 있다. 또한, 이에 더하여 타액에는 108~109CFU/㎖ 수준의 균수가 검출되고 있다. 치아는 미세한 구멍이 다수 개 천공되어 있어서 충치를 일으키는 세균이 상기한 구멍으로 들어가 치아를 병들게 하는데 이것이 충치이다. 이러한 충치는 치아에서 가장 흔히 볼 수 있는 대표적인 질환의 하나로 치아우식증이라고도 한다. 구강 내 음식물이 내산성 연쇄상 구균과 유산균에 의해 부패되고 산에 의해 치아의 성분이 파괴되는 감염성 세균성 질환이다. 우리나라에서는 영구 치아의 충치 이환율이 약 80%에 이르고, 한 사람이 평균 2~3개의 충치를 가지고 있는 것으로 보고되고 있다.More than 400 types of bacteria grow in the human oral cavity, and the number of bacteria reaches 10 billion. In addition, the number of bacteria at the level of 10 8 to 10 9 CFU/ml has been detected in saliva. Teeth are perforated with many tiny holes, so bacteria that cause cavities enter these holes and cause disease in the teeth, which is cavities. These cavities are one of the most common diseases seen in teeth and are also called dental caries. It is an infectious bacterial disease in which food in the oral cavity is decayed by acid-resistant streptococci and lactic acid bacteria, and tooth components are destroyed by acid. In Korea, the prevalence of tooth decay in permanent teeth is approximately 80%, and it is reported that each person has an average of 2 to 3 cavities.
충치를 일으키는 원인은 여러 가지가 복합적으로 작용하고 있는 것으로 밝혀져 있지만 가장 중요한 것은 치태이다. 치태에는 여러 세균이 섞여 있는데, 특히 내산성 연쇄상 구균과 유산균이 많고 그 중에서 스트렙토코쿠스 뮤탄스(Streptococcus mutans)가 주요 충치균으로 알려져 있다. 이같은 스트렙토코쿠스 뮤탄스는 치아의 표면에 부착하여 성장하면서 음식물 내의 당을 이용하여 산을 생성하여 치아를 부식시키고 동시에 치아 골세포에 침입하여 각종 치조 골 부식과 잇몸병을 발생시킨다. 좀더 자세하게는 충치의 발생은 충치 원인균에 의해서 치태가 치면에 형성하는 과정을 제1단계로 하고, 치태내에서 유기산이 생성되는 과정을 제2단계로, 치태내에서 생성된 유기산, 단백질 분해효소 등에 의해서 치아 표면을 구성하는 무기질을 탈회하고 나아가 유기질을 용해하여 가는 제3단계로 이루어진다. 또한 치주질환의 경우, 치면 및 치주 조직에 부착된 치태가 치주질환의 발생과 진행의 주된 원인이 되는 바, 치태내의 세균에 의해서 유해한 대사 산물이나 세균성 효소를 생성하여 그 결과로서 치은염을 유발시켜 발생하고 진전되는 것으로 알려져 있다. It has been revealed that the causes of cavities are a combination of many factors, but the most important one is plaque. Plaque contains a variety of bacteria, especially acid-resistant streptococci and lactic acid bacteria. Among them, Streptococcus mutans is known to be the main cavity-causing bacteria. As Streptococcus mutans attaches to the surface of the teeth and grows, it uses sugar in food to produce acid, which erodes the teeth and at the same time invades dental osteocytes, causing various types of alveolar bone erosion and gum disease. More specifically, the first stage in the development of cavities is the process in which plaque is formed on the tooth surface by cavity-causing bacteria, and the second stage is the process in which organic acids are produced within plaque, and the second stage is the process of organic acids and proteolytic enzymes produced within plaque. The third step is to demineralize the minerals that make up the tooth surface and further dissolve the organic substances. In addition, in the case of periodontal disease, plaque attached to the tooth surface and periodontal tissue is the main cause of the occurrence and progression of periodontal disease. Bacteria in the plaque produce harmful metabolites or bacterial enzymes, resulting in gingivitis. It is known to be progressing.
구취는 구강 및 인접기관으로부터 유래되는 냄새를 말하며 많은 사람들이 구취로 일상 생활에 불편을 호소하고 있다. 구취의 85~90%가 구강에서 유래하며, 특히, 혀의 뒷쪽에서 유래하고 있다. 구취의 주요 성분은 휘발성 황화합물인데, 휘발성 황화합물의 전체량 중 90%가 시스테인으로부터 만들어지는 황화수소(hydrogen sulfide)와 메치오닌으로부터 만들어지는 메틸머캡탄(methyl mercaptan) 및 디메틸설파이드(dimethyl sulfide)이다. 이러한 성분들은 주로 혐기성 세균이 분비하는 단백질 효소에 의해서 생성되며, 혀의 뒷쪽이 가장 중요한 서식지가 된다. 이 부위는 타액에 의해 세정작용이 잘 되지 않고, 많은 작은 함몰이 있어 세균이 지속적으로 살아가는 장소가 된다. 혐기성 세균에 의한 휘발성 황화합물 생성이 구취의 원인으로 가장 중요하지만, 그 외 충치와 치주염 등과 같은 구강질환에 의해서도 발생한다. 구취를 발생시키는데 많은 종류의 혐기성 세균이 관여하지만, 특히, 구취 발생의 대표적인 세균은 많은 종류와 많은 양의 효소를 분비하는 포르피로모나스 진지발리스(Porphyromonas gingivalis), 프레보텔라 인터메디아(Prevotella intermedia), 푸소박테리움 누클레아툼(Fusobacterium nucleatum), 박테오이데스 포르시두스(Bacteoides forsythus), 트레포네마 데티코라(Treponema deticola) 등으로서, 치주염을 일으키는 대표적인 원인균으로도 알려져 있다. 구취를 억제하기 위해서는 구취의 주성분인 휘발성 황화합물을 생성하는 혐기성 세균의 증식을 억제하는 것이 가장 효과적이기 때문에, 종래에는 혀로부터 세균의 증식기질을 제거하기 위해 혀 세정기(tongue scraper)를 사용하여 설태를 제거하거나, 혐기성 세균의 증식이나 혐기성 세균에 의한 휘발성 황화합물 생성을 억제하기 위하여 염화아연(zinc chloride)과 같은 금속염 또는 알콜이나 클로르헤시딘(chlorhexidine)과 같은 소독제를 사용하였다. 그러나, 이러한 금속염이나 소독제는 구취를 발생시키는 혐기성 세균뿐만 아니라 구강내 다른 미생물까지도 발생을 억제하며, 이러한 물질은 식도로 삼키지 않기 때문에 구취 발생에 있어서 중요한 장소인 혀의 뒷쪽까지 가지 못하고 구강 앞쪽에서 주로 가글링되고 입밖으로 뱉어내어 진다. 그래서, 구취 발생 혐기성 세균의 주요한 증식 장소인 혀 뒤쪽까지는 소독할 수 없다는 문제점이 있다. 또한, 이러한 물질은 타액에 의해서 희석되고 타액과 함께 식도로 삼켜져 구강에서의 효과는 20분 내지 2시간 정도뿐이고, 그 후 구강에는 미생물이 다시 증식하여 구취가 발생하게 된다. 따라서, 구취를 감소시키기 위하여 사용되고 있는 금속염이나 소독제는 그 효과가 단기간에 불과하고, 구취 재발이 빈번하다.Bad breath refers to odor originating from the oral cavity and adjacent organs, and many people complain of inconvenience in their daily lives due to bad breath. 85-90% of bad breath originates from the mouth, especially the back of the tongue. The main components of bad breath are volatile sulfur compounds, and 90% of the total amount of volatile sulfur compounds are hydrogen sulfide made from cysteine, and methyl mercaptan and dimethyl sulfide made from methionine. These ingredients are mainly produced by protein enzymes secreted by anaerobic bacteria, and the back of the tongue is their most important habitat. This area is not cleaned well by saliva and has many small depressions, making it a place where bacteria continue to live. The production of volatile sulfur compounds by anaerobic bacteria is the most important cause of bad breath, but it can also be caused by other oral diseases such as cavities and periodontitis. Many types of anaerobic bacteria are involved in causing bad breath, but in particular, the representative bacteria causing bad breath are Porphyromonas gingivalis and Prevotella intermedia , which secrete many types and large amounts of enzymes. ), Fusobacterium nucleatum , Bacteoides forsythus , Treponema deticola , etc., are also known as representative causative bacteria that cause periodontitis. In order to suppress bad breath, it is most effective to suppress the growth of anaerobic bacteria that produce volatile sulfur compounds, the main component of bad breath. Conventionally, tongue scrapers are used to remove bacterial growth substrates from the tongue. To remove or inhibit the growth of anaerobic bacteria or the production of volatile sulfur compounds by anaerobic bacteria, metal salts such as zinc chloride or disinfectants such as alcohol or chlorhexidine were used. However, these metal salts and disinfectants suppress the development of not only anaerobic bacteria that cause bad breath, but also other microorganisms in the oral cavity, and since these substances are not swallowed through the esophagus, they do not reach the back of the tongue, which is an important place in the occurrence of bad breath, and are mainly stored in the front of the mouth. It is gargled and spit out of the mouth. Therefore, there is a problem that the back of the tongue, which is the main growth site of anaerobic bacteria that cause bad breath, cannot be disinfected. In addition, these substances are diluted by saliva and swallowed into the esophagus along with saliva, so the effect in the oral cavity is only about 20 minutes to 2 hours, and then microorganisms proliferate again in the oral cavity, causing bad breath. Therefore, metal salts or disinfectants used to reduce bad breath are only effective for a short period of time, and bad breath frequently recurs.
최근에는 유산균을 이용하여 혐기성 세균의 증식을 억제하고자 하는 시도가 있었으나(대한민국등록특허 제10-1062779호 등), 이러한 유산균은 구강에 투여하면 금속염이나 소독제와 같이 타액에 의해 희석이 되면서 식도로 바로 삼켜져 구강에 잔류하기가 어렵다. 게다가 유산균의 산 성분은 충치를 일으키기 때문에 구강에 장기간 투여하면 구강 위생에 좋지 않다는 문제점이 있다. Recently, there have been attempts to suppress the growth of anaerobic bacteria using lactic acid bacteria (Korean Patent No. 10-1062779, etc.). However, when these lactic acid bacteria are administered orally, they are diluted by saliva like metal salts or disinfectants and enter the esophagus directly. It is difficult to swallow and remain in the oral cavity. In addition, because the acid component of lactic acid bacteria causes cavities, there is a problem that it is not good for oral hygiene when administered to the oral cavity for a long period of time.
치약은 치아의 표면을 잇솔질할 때 사용하는 의약부외품으로서, 특히 미백효과, 살균효과, 치간청정효과 등을 목적으로 주로 사용하며, 이를 위하여 일반적으로 치약은 연마제, 습윤제, 기포제, 감미제와 같은 성분들을 포함하여 이루어진다. 최근에는 충치, 치주염, 구취 억제 효과를 개선하기 위한 다양한 기능성 치약의 제조를 위한 연구가 많이 진행되고 있다. 게다가 최근에 치주 질환은 단순한 잇몸 조직의 만성 감염에 그치지 않고, 심근경색, 동맥경화를 비롯하여 당뇨병, 조산(早産) 유발 등의 위험인자로서 주목을 받고 있다. 따라서 치약 사용이 각종 건강 상태를 호전시킬 수 있는 기반이 될 가능성을 암시하기도 한다. 한편, 일반적으로 충치나 치주염을 예방하기 위해 치약이나 구강청정제에 0.05~0.1. w/v% 농도의 불소가 자주 사용되는데, 최근의 보고에 의하면 치약이나 구강청정제 등에서 불소화합물의 사용이 치아의 우식증은 예방할 수는 있지만, 장기적이고 반복적인 불소화합물 사용은 잇몸에 염증 현상을 촉진하는 것으로 밝혀지고 있다. 따라서, 불소를 사용하지 않으면서도 시린 이 현상을 억제하고 치아 우식증을 예방할 수 있는 치약 조성물이 요구되고 있다. Toothpaste is a quasi-drug used when brushing the surface of teeth, and is mainly used for whitening, sterilizing, and interdental cleaning effects. For this purpose, toothpaste generally contains ingredients such as abrasives, humectants, foaming agents, and sweeteners. It is done including. Recently, much research has been conducted to manufacture various functional toothpastes to improve the effects of suppressing cavities, periodontitis, and bad breath. Moreover, periodontal disease has recently been attracting attention as not only a chronic infection of gum tissue, but also as a risk factor for myocardial infarction, arteriosclerosis, diabetes, and premature birth. Therefore, it suggests that the use of toothpaste may serve as a foundation for improving various health conditions. Meanwhile, in general, 0.05 to 0.1 is added to toothpaste or mouthwash to prevent cavities or periodontitis. Fluoride at a w/v% concentration is often used. According to recent reports, the use of fluoride compounds in toothpaste or mouthwash can prevent dental caries, but long-term and repeated use of fluoride compounds promotes inflammation in the gums. It turns out that it does. Therefore, there is a need for a toothpaste composition that can suppress the phenomenon of sensitive teeth and prevent dental caries without using fluoride.
유칼립투스는 오가피(Eleutherococcus sessiliflorus 또는 Acanthopanax sessiliflorus)의 열매로서, 뿌리껍질이나 나무껍질은 오갈피 또는 오가피라 하여 약용하며 다양한 생리활성이 알려져 있지만, 현재까지 오가피 열매에 대한 연구는 거의 이루어지지 않고 있다. Eucalyptus is the fruit of Eleutherococcus sessiliflorus or Acanthopanax sessiliflorus , and the root bark or bark is called Eucalyptus or Eucalyptus for medicinal purposes and is known to have various physiological activities, but little research has been done on the fruit to date.
한편 본 발명자들은 치약 원료로 사용할 수 있는 각 성분에 대한 다양한 생리활성을 연구하던 중, 각종 생약의 복합 추출물이 치아우식증, 치주질환, 구취와 관련된 각종 균주의 억제 효과가 있음을 확인하여 본 발명을 완성하였다. Meanwhile, while researching the various physiological activities of each ingredient that can be used as a toothpaste raw material, the present inventors confirmed that complex extracts of various herbal medicines have an inhibitory effect on various strains related to dental caries, periodontal disease, and bad breath, and thus developed the present invention. Completed.
본 발명의 목적은 생약 추출물을 함유하는 구강케어 치약 조성물을 제공하는 데에 있다. The purpose of the present invention is to provide an oral care toothpaste composition containing herbal extracts.
본 발명은 생약 추출물을 함유하는 구강케어 치약 조성물에 관한 것으로서, 자세하게는 유칼립투스 추출물, 쑥 추출물, 황금 추출물, 인삼 추출물, 병풀 추출물 및 티트리 추출물이 혼합된 생약 추출물을 함유하는 구강케어 치약 조성물에 관한 것이다.The present invention relates to an oral care toothpaste composition containing a herbal extract, and more specifically, to an oral care toothpaste composition containing a herbal extract mixed with eucalyptus extract, mugwort extract, goldenrod extract, ginseng extract, centella asiatica extract, and tea tree extract. will be.
상기 생약 추출물은 유칼립투스 추출물 100 중량부 기준으로 쑥 추출물 20~250 중량부, 황금 추출물 20~250 중량부, 인삼 추출물 20~250 중량부, 병풀 추출물 20~250 중량부 및 티트리 추출물 1400~2400 중량부가 함유된 것일 수 있다. The herbal extract is 20-250 parts by weight of mugwort extract, 20-250 parts by weight of golden extract, 20-250 parts by weight of ginseng extract, 20-250 parts by weight of Centella asiatica extract, and 1400-2400 parts by weight of tea tree extract, based on 100 parts by weight of eucalyptus extract. It may contain additives.
상기 생약 추출물은 치약 조성물에 0.2~2 중량%로 함유될 수 있다.The herbal extract may be contained in 0.2 to 2% by weight in the toothpaste composition.
상기 치약 조성물에는 이산화규소, 알란토인클로로히드록시알루미늄, 아미노카프로산, 농글리세린, D-소르비톨액, 잔탄검, 락토페린, 자일리톨, 아미노카프로산, 코코일글루타민산나트륨, 매스틱오일 및 정제수가 포함될 수 있다. The toothpaste composition may include silicon dioxide, allantoin chlorohydroxyaluminum, aminocaproic acid, concentrated glycerin, D-sorbitol solution, xanthan gum, lactoferrin, xylitol, aminocaproic acid, sodium cocoyl glutamate, mastic oil and purified water. .
이 때, 상기 치약 조성물에, 이산화규소 10~20 중량%, 알란토인클로로히드록시알루미늄 0.01~0.1 중량%, 아미노카프로산 0.02~0.2 중량%, 농글리세린 1~5 중량%, D-소르비톨액 40~60 중량%, 잔탄검 0.5~1.2 중량%, 락토페린 0.05~0.2 중량%, 자일리톨 0.01~0.1 중량%, 아미노카프로산 0.01~1 중량%, 코코일글루타민산나트륨 0.5~3 중량%, 매스틱오일 0.05~0.5 중량% 및 정제수 15~40 중량%가 포함될 수 있다. At this time, the toothpaste composition contains 10 to 20% by weight of silicon dioxide, 0.01 to 0.1% by weight of allantoin chlorohydroxyaluminum, 0.02 to 0.2% by weight of aminocaproic acid, 1 to 5% by weight of concentrated glycerin, and 40 to 40% of D-sorbitol solution. 60% by weight, xanthan gum 0.5~1.2% by weight, lactoferrin 0.05~0.2% by weight, xylitol 0.01~0.1% by weight, aminocaproic acid 0.01~1% by weight, sodium cocoyl glutamate 0.5~3% by weight, mastic oil 0.05~ It may contain 0.5% by weight and 15-40% by weight of purified water.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 유칼립투스 추출물, 쑥 추출물, 황금 추출물, 인삼 추출물, 병풀 추출물 및 티트리 추출물이 혼합된 생약 추출물을 함유하는 치약 조성물에 관한 것이다. The present invention relates to a toothpaste composition containing a herbal extract mixed with eucalyptus extract, mugwort extract, goldenrod extract, ginseng extract, centella asiatica extract, and tea tree extract.
상기 치약 조성물은 충치 원인균인 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 균주에 대한 항균 효과가 있는 것을 특징으로 한다. The toothpaste composition is characterized by an antibacterial effect against Streptococcus mutans strain, which is a cavity-causing bacteria.
상기 치약 조성물은 치주염 또는 구취의 원인균인 포르피로모나스 진지발리스(Porphyromonas gingivalis), 프레보텔라 인터메디아(Prevotella intermedia), 푸소박테리움 누클레아툼(Fusobacterium nucleatum), 박테오이데스 포르시두스(Bacteoides forsythus) 및 트레포네마 데티코라(Treponema deticola)로 이루어진 군 중에서 선택된 1종 이상의 균주에 대한 항균 효과가 있는 것을 특징으로 한다. The toothpaste composition contains bacteria that cause periodontitis or bad breath, such as Porphyromonas gingivalis , Prevotella intermedia , Fusobacterium nucleatum , and Bacteoides porcidus ( It is characterized by an antibacterial effect against one or more strains selected from the group consisting of Bacteoides forsythus ) and Treponema deticola .
상기 생약 추출물은 유칼립투스 추출물 100 중량부 기준으로 쑥 추출물 20~250 중량부, 황금 추출물 20~250 중량부, 인삼 추출물 20~250 중량부, 병풀 추출물 20~250 중량부 및 티트리 추출물 1400~2400 중량부가 함유된 것일 수 있는데, 각 원료의 함량범위가 이를 벗어나게 되면 치태나 치석 생성 억제능이나 항균 효과 또는 구취 억제 효과가 경감될 수 있어 바람직하지 않다. The herbal extract is 20-250 parts by weight of mugwort extract, 20-250 parts by weight of golden extract, 20-250 parts by weight of ginseng extract, 20-250 parts by weight of Centella asiatica extract, and 1400-2400 parts by weight of tea tree extract, based on 100 parts by weight of eucalyptus extract. It may contain additional ingredients, but if the content range of each raw material exceeds this range, the ability to inhibit plaque or tartar formation, the antibacterial effect, or the bad breath inhibition effect may be reduced, which is not desirable.
상기 치약 조성물에는 유칼립투스 추출물 100 중량부 기준으로 L-라이신 0.1~5 중량부가 첨가될 수 있는데, L-라이신의 첨가를 통해 잇몸이 약해지는 것을 억제한다. 0.1 to 5 parts by weight of L-lysine may be added to the toothpaste composition based on 100 parts by weight of eucalyptus extract, and the addition of L-lysine suppresses weakening of the gums.
상기 생약 추출물은 치약 조성물에 0.2~2 중량%로 함유될 수 있다. The herbal extract may be contained in 0.2 to 2% by weight in the toothpaste composition.
또한 본 발명의 치약 조성물에는 이산화규소, 알란토인클로로히드록시알루미늄, 아미노카프로산, 농글리세린, D-소르비톨액, 락토페린, 자일리톨, 아미노카프로산, 코코일글루타민산나트륨, 매스틱오일 및 정제수가 포함될 수 있는데, 이 때, 바람직하게는 이산화규소 10~20 중량%, 알란토인클로로히드록시알루미늄 0.01~0.1 중량%, 아미노카프로산 0.02~0.2 중량%, 농글리세린 1~5 중량%, D-소르비톨액 40~60 중량%, 락토페린 0.05~0.2 중량%, 자일리톨 0.01~0.1 중량%, 아미노카프로산 0.01~1 중량%, 코코일글루타민산나트륨 0.5~3 중량%, 매스틱오일 0.05~0.5 중량% 및 정제수 15~40 중량%가 포함될 수 있다. 이 때 각 구성성분의 함량이 이 범위를 벗어나게 되면 치약 조성물의 물성이 잘 유지되지 않거나 생약 추출물을 포함하는 치약의 보존 효과가 나빠질 수 있다. 또한 치약 조성물의 항균 및 구취 억제 효과가 경감될 수도 있다. Additionally, the toothpaste composition of the present invention may include silicon dioxide, allantoin chlorohydroxyaluminum, aminocaproic acid, concentrated glycerin, D-sorbitol solution, lactoferrin, xylitol, aminocaproic acid, sodium cocoyl glutamate, mastic oil, and purified water. , at this time, preferably 10 to 20% by weight of silicon dioxide, 0.01 to 0.1% by weight of allantoin chlorohydroxyaluminum, 0.02 to 0.2% by weight of aminocaproic acid, 1 to 5% by weight of concentrated glycerin, and 40 to 60% by weight of D-sorbitol solution. Weight%, lactoferrin 0.05~0.2% by weight, xylitol 0.01~0.1% by weight, aminocaproic acid 0.01~1% by weight, sodium cocoyl glutamate 0.5~3% by weight, mastic oil 0.05~0.5% by weight, and purified water 15~40% by weight. % may be included. At this time, if the content of each component is outside this range, the physical properties of the toothpaste composition may not be maintained well or the preservation effect of the toothpaste containing herbal extract may deteriorate. Additionally, the antibacterial and bad breath inhibition effects of the toothpaste composition may be reduced.
상기 유칼립투스 추출물은 오가피나무의 종자인 유칼립투스를 물, C1~C4 알코올 또는 이들의 혼합용액을 용매로 하여 추출할 수 있으며, 상기 C1~C4 알코올은 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 및 이소부탄올로 이루어진 군에서 선택될 수 있다. The eucalyptus extract can be extracted from eucalyptus, which is a seed of the Eucalyptus tree, using water, C1 to C4 alcohol, or a mixed solution thereof as a solvent, and the C1 to C4 alcohol is methanol, ethanol, propanol, isopropanol, butanol, and isobutanol. It can be selected from a group consisting of:
상기 추출물의 제조시 사용되는 물, C1~C4 알코올 또는 이들의 혼합용액은 식물 또는 종자 사용 중량 기준 1~40배 부피(1kg 기준 1~40ℓ)를 사용할 수 있으며, 바람직하게는 5~40배 부피를 사용할 수 있다. 상기 추출물의 추출조건은 20~100℃에서 1분~48시간일 수 있다. 상기 과정은 1~4번까지 반복할 수 있다. 상기 추출물의 제조온도는 20 내지 100℃일 수 있으나, 이에 제한되는 것은 아니다. 추출 시간은 특별히 제한되는 것은 아니나, 10분 내지 2일 이내에 추출하는 것이 바람직하며, 추출용 기기로는 통상의 추출기기, 초음파분쇄추출기 또는 분획기를 이용할 수 있다. 이렇게 제조된 각 추출물은 열풍건조, 감압건조 또는 동결건조하여 용매를 제거할 수 있다. Water, C1 to C4 alcohol, or a mixed solution thereof used in the preparation of the extract can be used in an amount of 1 to 40 times the volume (1 to 40 liters per kg) based on the weight of plants or seeds used, and preferably 5 to 40 times the volume. can be used. Extraction conditions for the extract may be 1 minute to 48 hours at 20 to 100°C. The above process can be repeated 1 to 4 times. The manufacturing temperature of the extract may be 20 to 100°C, but is not limited thereto. The extraction time is not particularly limited, but is preferably extracted within 10 minutes to 2 days, and the extraction device may be a conventional extraction device, an ultrasonic grinding extractor, or a fractionator. Each extract prepared in this way can be dried with hot air, dried under reduced pressure, or freeze-dried to remove the solvent.
본 발명에서 사용되는 유칼립투스 추출물의 고형분 함량은 1~90 중량%일 수 있다. The solid content of the eucalyptus extract used in the present invention may be 1 to 90% by weight.
한편, 본 발명에서 가장 바람직하게 사용할 수 있는 유칼립투스 추출물은 원료 시료대비 30~90%(v/v) 에탄올 수용액 1 중량 대비 5~20 배 부피(1kg 당 5~20ℓ)로 가하여 얻은 추출액을 감암농축한 것을 사용하는 것이 좋다. On the other hand, the eucalyptus extract that can be most preferably used in the present invention is concentrated in the dark by adding 5 to 20 times the volume (5 to 20 liters per 1 kg) of 30 to 90% (v/v) ethanol aqueous solution compared to the raw material sample. It is better to use one.
본 발명은 타나아제, 황금 추출물, 인삼 추출물, 병풀 추출물 및 티트리 추출물이 혼합된 생약 추출물을 함유하는 치약 조성물에 관한 것으로서, 상기 조성물은 충치, 치주염 또는 구취의 원인균에 대한 항균효과가 우수하다. The present invention relates to a toothpaste composition containing a herbal extract mixed with tanase, goldenrod extract, ginseng extract, centella asiatica extract, and tea tree extract. The composition has excellent antibacterial effect against bacteria that cause cavities, periodontitis, or bad breath.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지도록, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided to ensure that the content introduced here is thorough and complete, and to sufficiently convey the spirit of the present invention to those skilled in the art.
<실시예 1. 생약 추출물의 제조><Example 1. Preparation of herbal extract>
하기 표 1의 성분비로 각종 추출물을 혼합하여 생약 추출물을 제조하였다. 각 추출물은 원료 시료 대비 70%(v/v) 에탄올 수용액을 10 배 부피(1kg 당 10ℓ)로 가하여 얻은 추출액을 감암농축한 것을 사용하였다. 실시예 1-7은 잇몸 질환의 예방을 위해 L-라이신을 첨가하였다. Herbal extracts were prepared by mixing various extracts in the ingredient ratios shown in Table 1 below. For each extract, an extract obtained by adding 10 times the volume (10 liters per kg) of 70% (v/v) ethanol aqueous solution compared to the raw material sample was used. In Examples 1-7, L-lysine was added to prevent gum disease.
추출물 (g)eucalyptus
Extract (g)
추출물(g)Gold
Extract (g)
추출물 (g)Ginseng
Extract (g)
추출물 (g)Centella asiatica
Extract (g)
추출물 (g)tea tree
Extract (g)
<실시예 2. 치약 조성물의 제조><Example 2. Preparation of toothpaste composition>
하기 표 2의 성분비로 생약 추출물과 각 성분들을 혼합하여 치약을 제조하였다. Toothpaste was prepared by mixing the herbal extract and each component in the component ratio shown in Table 2 below.
(실시예 1-1)0.25
(Example 1-1)
(실시예 1-3)0.25
(Example 1-3)
(실시예 1-7)0.25
(Example 1-7)
(실시예 1-7)0.2
(Example 1-7)
(실시예 1-1)2
(Example 1-1)
<비교예 1. 비교 조성물의 제조><Comparative Example 1. Preparation of comparative composition>
하기 표 3의 성분비로 각 추출물을 혼합하여 비교 조성물을 제조하였다. A comparative composition was prepared by mixing each extract in the ingredient ratio shown in Table 3 below.
추출물 (g)eucalyptus
Extract (g)
추출물 (g)Mugwort
Extract (g)
추출물 (g)Gold
Extract (g)
추출물 (g)Ginseng
Extract (g)
추출물 (g)Centella asiatica
Extract (g)
추출물 (g)tea tree
Extract (g)
<비교예 2. 비교 치약 조성물의 제조><Comparative Example 2. Preparation of comparative toothpaste composition>
하기 표 4의 성분비로 생약 추출물과 각 성분들을 혼합하여 치약을 제조하였다. Toothpaste was prepared by mixing the herbal extract and each component in the component ratio shown in Table 4 below.
(실시예 1-1 생약 추출물)3.75
(Example 1-1 Herbal Medicine Extract)
<실험예 1. 항균 효과 확인><Experimental Example 1. Confirmation of antibacterial effect>
스트렙토코쿠스 뮤탄스, 포르피로모나스 진지발리스, 프레보텔라 인터메디아를 헤민 메나디온(hemin menadione)이 첨가된 TSA(trypticase soy agar) 배지에 배양한 후, 최소생육억제농도(MIC)를 측정하였고 이를 표 5에 나타내었다. 이 때, 생약 추출물은 고형분 함량이 0~1000 ㎍/㎖이 되도록 희석하였고, 각 균주(세균)는 O.D.600 = 0.2로 농도를 조절하여 사용하였다. 96-웰 플레이트(96-well plate, Falcon, USA)에 본 발명에 사용된 세균 배양용 헤민 메나디온이 첨가된 TSB(trypticase soy broth) 100 ㎖, 생약 추출물 희석 용액 50 ㎖, 균주 희석액 50 ㎖를 순차적으로 첨가한 뒤 4 시간마다 UV-스펙트로포토미터(spectrophotometer)를 이용해 흡광도 값을 측정하면서 24 시간 동안 37 ℃에서 배양하였다. 이때, 세균의 생육 곡선상에서 균주의 생장(turbidity)이 검출되지 않는 최소농도를 최소생육억제농도로 설정하였다.Streptococcus mutans, Porphyromonas gingivalis, and Prevotella intermedia were cultured on TSA (trypticase soy agar) medium supplemented with hemin menadione, and then the minimum growth inhibitory concentration (MIC) was measured. and this is shown in Table 5. At this time, the herbal extract was diluted so that the solid content was 0 to 1000 ㎍/㎖, and each strain (bacteria) was used by adjusting the concentration to OD.600 = 0.2. In a 96-well plate (Falcon, USA), 100 ml of TSB (trypticase soy broth) supplemented with hemin menadione for bacterial culture used in the present invention, 50 ml of herbal extract dilution solution, and 50 ml of strain dilution solution were placed in a 96-well plate (Falcon, USA). After sequential addition, the mixture was incubated at 37°C for 24 hours while measuring the absorbance value using a UV-spectrophotometer every 4 hours. At this time, the minimum concentration at which turbidity of the strain was not detected on the bacterial growth curve was set as the minimum growth inhibition concentration.
상기 표 5의 결과를 참고하면 본 발명의 실시예 1-1 내지 1-7의 조성물이 갖는 구강내 세균에 대한 항균 효과가 비교예 1-1 내지 1-6의 조성물에 비해 현저하게 우수함을 알 수 있다. 이와 같은 미생물 대치 결과는 푸소박테리움 누클레아툼, 박테오이데스 포르시두스 및 트레포네마 데티코라와의 대치실험에서도 유사하게 나타났다.Referring to the results in Table 5, it can be seen that the antibacterial effect on oral bacteria of the compositions of Examples 1-1 to 1-7 of the present invention is significantly superior to that of the compositions of Comparative Examples 1-1 to 1-6. You can. These microbial replacement results were similar in replacement experiments with Fusobacterium nucleatum, Bacteoides forcidus, and Treponema deticora.
<실험예 2. 치약 사용에 따른 관능평가><Experimental Example 2. Sensory evaluation according to the use of toothpaste>
본 발명 실시예 2 및 비교예 2의 치약을 50명의 성인남녀에게 분배하고 2개월 간 사용 후 구취 및 잇몸 염증 억제 효과를 기존에 시판되는 일반 치약을 사용했던 결과와 비교하게 하였으며 그 결과는 5점 타점법으로 나타내었다(1점:아주나쁨, 2점:나쁨, 3점:보통, 4점:좋음, 5점:아주좋음). The toothpaste of Example 2 and Comparative Example 2 of the present invention was distributed to 50 adult men and women, and after use for 2 months, the effect of suppressing bad breath and gum inflammation was compared with the results of using a commercially available general toothpaste, and the result was 5 points. It was expressed using the RBI method (1 point: very bad, 2 points: bad, 3 points: average, 4 points: good, 5 points: very good).
표 6의 결과를 참고하면, 실시예 2의 치약을 사용하는 사람들이 비교예 2의 치약을 사용하는 사람들에 비해 구취 억제 효과와 잇몸 염증 억제 효과가 더 좋다는 평가를 내린 것으로 확인된다. 또한 치약 중에서도 실시예 2-3의 치약이 가장 높은 효과가 있는 것을 알 수 있다. 비교예 2-2의 치약의 경우, 생약 추출물이 함유되기는 하였으나 치약 부형제와의 혼합조건에 따른 제형상의 특성 상 구취 억제 효과와 잇몸 염증 억제 효과가 줄어든 것으로 판단된다. Referring to the results in Table 6, it is confirmed that people using the toothpaste of Example 2 evaluated the effect of suppressing bad breath and gum inflammation to be better than those using the toothpaste of Comparative Example 2. In addition, it can be seen that among the toothpastes, the toothpaste of Example 2-3 has the highest effect. In the case of the toothpaste of Comparative Example 2-2, although it contained herbal extracts, the effects of suppressing bad breath and suppressing gum inflammation were judged to be reduced due to the characteristics of the formulation according to the mixing conditions with toothpaste excipients.
Claims (5)
상기 치약 조성물에는 이산화규소, 알란토인클로로히드록시알루미늄, 아미노카프로산, 농글리세린, D-소르비톨액, 잔탄검, 락토페린, 자일리톨, 아미노카프로산, 코코일글루타민산나트륨, 매스틱오일 및 정제수가 포함되는 것을 특징으로 하는 치약 조성물.According to paragraph 1,
The toothpaste composition includes silicon dioxide, allantoin chlorohydroxyaluminum, aminocaproic acid, concentrated glycerin, D-sorbitol solution, xanthan gum, lactoferrin, xylitol, aminocaproic acid, sodium cocoyl glutamate, mastic oil, and purified water. Characterized toothpaste composition.
상기 생약 추출물에 L-라이신이 첨가된 것을 특징으로 하는 치약 조성물. According to paragraph 1,
A toothpaste composition characterized in that L-lysine is added to the herbal extract.
상기 치약 조성물은 충치 원인균인 스트렙토코쿠스 뮤탄스 균주에 대한 항균 효과가 있는 것을 특징으로 하는 치약 조성물. According to paragraph 1,
The toothpaste composition is characterized in that it has an antibacterial effect against Streptococcus mutans strain, which is a cavity-causing bacteria.
상기 치약 조성물은 치주염 또는 구취의 원인균인 포르피로모나스 진지발리스, 프레보텔라 인터메디아, 푸소박테리움 누클레아툼, 박테오이데스 포르시두스 및 트레포네마 데티코라로 이루어진 군 중에서 선택된 1종 이상의 균주에 대한 항균 효과가 있는 것을 특징으로 하는 치약 조성물. According to paragraph 1,
The toothpaste composition is one selected from the group consisting of Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, Bacteoides forsidus, and Treponema deticora, which are bacteria causing periodontitis or bad breath. A toothpaste composition characterized by an antibacterial effect against more than one type of strain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220088861A KR20240011429A (en) | 2022-07-19 | 2022-07-19 | Oral care toothpaste composition containing herbal extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220088861A KR20240011429A (en) | 2022-07-19 | 2022-07-19 | Oral care toothpaste composition containing herbal extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240011429A true KR20240011429A (en) | 2024-01-26 |
Family
ID=89714541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220088861A KR20240011429A (en) | 2022-07-19 | 2022-07-19 | Oral care toothpaste composition containing herbal extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240011429A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030093891A (en) | 2002-06-05 | 2003-12-11 | 김희성 | PROPOLIS Toothpaste COMPOSITION AND PROCESS FOR PREPARING THE SAME |
KR101062779B1 (en) | 2010-04-28 | 2011-09-06 | 삼육대학교산학협력단 | Bifidobacterium adolescentis inhibiting the growth of streptococcus mutans and foodstuffs and pharmaceutical composition for preventing tooth decay containing bifidobacterium adolescentis or its culture |
KR101198634B1 (en) | 2009-10-07 | 2012-11-07 | 한국교통대학교산학협력단 | Natural edible anti-microbial film composition and method of manufacturing the same |
KR101494436B1 (en) | 2013-04-23 | 2015-02-24 | 대한민국 | Novel compound from the fruits of Acanthopanax sessiliflorus |
KR20170054314A (en) | 2015-11-09 | 2017-05-17 | 대한민국(농촌진흥청장) | Composition comprising extract of Eleutherococcus sessiliflorus fruits for prevention and treatment of allergic diseases or inflammatory diseases |
-
2022
- 2022-07-19 KR KR1020220088861A patent/KR20240011429A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030093891A (en) | 2002-06-05 | 2003-12-11 | 김희성 | PROPOLIS Toothpaste COMPOSITION AND PROCESS FOR PREPARING THE SAME |
KR101198634B1 (en) | 2009-10-07 | 2012-11-07 | 한국교통대학교산학협력단 | Natural edible anti-microbial film composition and method of manufacturing the same |
KR101062779B1 (en) | 2010-04-28 | 2011-09-06 | 삼육대학교산학협력단 | Bifidobacterium adolescentis inhibiting the growth of streptococcus mutans and foodstuffs and pharmaceutical composition for preventing tooth decay containing bifidobacterium adolescentis or its culture |
KR101494436B1 (en) | 2013-04-23 | 2015-02-24 | 대한민국 | Novel compound from the fruits of Acanthopanax sessiliflorus |
KR20170054314A (en) | 2015-11-09 | 2017-05-17 | 대한민국(농촌진흥청장) | Composition comprising extract of Eleutherococcus sessiliflorus fruits for prevention and treatment of allergic diseases or inflammatory diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
KR20150027352A (en) | Mouthwash Composition Using Natural Materials and the Manufacturing Method Thereof | |
KR101480690B1 (en) | Oral composition containing natural agent | |
KR20200012181A (en) | Toothpaste composition comprising herbal extract mixture as effective component | |
KR102207872B1 (en) | Oral composition for preventation or treatment of oral disease | |
KR102162661B1 (en) | Toothpaste Composition Comprising Rosa Canina Extract | |
KR102636026B1 (en) | Composition for prevention or trreatment of dental disease comprising an extract of Thalictrum aquilegiifolium | |
KR102054336B1 (en) | Antibacterial brush bristles making method for using natural material having non-toxic oral health function | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
KR20110088978A (en) | Oral composition containing herbal extract | |
KR20220085035A (en) | Composition for improving oral health comprising extracts of Stewartia koreana Nakai and the product comprising the same | |
KR102216382B1 (en) | Oral health care composition containing phytosalt-containing nipapam-derived complex natural product as an active ingredient, method for manufacturing the same, and oral health care product manufactured using the composition | |
KR20240011429A (en) | Oral care toothpaste composition containing herbal extract | |
KR101632910B1 (en) | Mouth spray composition comprising cypress extracts and medical herb extracts and manufacturing method thereof | |
KR20220099175A (en) | Oral composition comprising herbal complex | |
KR101078765B1 (en) | Edible composition for prevention of periodontal disease by growth of bacteria in the mouth | |
KR20190124073A (en) | Composition containing Juniperus rigida siebold and Zucc extracts for preventing the formation of biofilm of microorganism | |
KR102575768B1 (en) | Natural Edible Film Compositions for Preventing or Improving Oral Diseases and Uses Thereof | |
KR20190094986A (en) | Composition for prevention or treatment of oral disease comprising Epimedium Herb extract | |
KR102540804B1 (en) | Composition containing Torreya nucifera extracts for preventing the formation of biofilm of mmicroorgaism | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
SAGAR et al. | ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF HERBAL FORMULATION (FICUS BENGHALENIS, AZADIRACHTA INDICA AND MENTHA PIPERITA) BASED MOUTHWASH. | |
KR20230040578A (en) | Composition for Inhibiting Biofilm Formation and for Preventing or Treating Dental Disease |